In patients with T2D, physiological secretion of GIP or GLP-1 decreases, thus reducing insulin secretion, compared to that in healthy participants.28 Notably, DPP-4 inhibitors enhance GLP-1 or GIP level in patients with T2D. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.